Xencor Trial Results Webcast - XENCOR INC

Financial Performance:

• No specific revenue, earnings, or cash flow figures disclosed; company remains in clinical development stage with no commercial products launched.
• Manufacturing capabilities confirmed with high-titer cell banks scalable to 2,000 liters and drug substance/product stability for 60 months in liquid formulation.
• Commercially validated CDMOs utilized for U.S. manufacturing, supporting potential blockbuster status for XMAP819 in the $11+ billion global renal cell carcinoma (RCC) market.

Guidance and Future Outlook:

• XMAP819 Phase 3 (pivotal) study expected to initiate in 2027 with a target dose of 400 µg/kg IV.
• FDA End-of-Phase I meeting planned for the first half of 2027 to discuss accelerated approval pathway and confirmatory study design.
• Primary registration-enabling study design aims for a control arm of Tivozinib to support full approval in the third-line advanced clear cell RCC setting.
• Goal to achieve broad regulatory approvals across treatment lines starting by 2030, with XMAP819 as the first wholly owned commercial-stage program.
• Subcutaneous (Sub-Q) formulation data expected in the first half of 2027 to inform dosing convenience and potential commercial lifecycle strategies.

Business Segments and Product Lines:

• XMAP819 (Lead Asset): T-cell engager targeting ENPP3 for solid tumors; demonstrated dose-dependent efficacy in Clear Cell RCC with 45.5% ORR at 400 µg/kg.
• Basket Trials: Expanded to Papillary RCC, Microsatellite-Stable (MSS) Colorectal Cancer, and Non-Squamous Non-Small Cell Lung Cancer (NSCLC) based on ENPP3 expression; enrollment contingent on IHC screening for non-RCC indications.
• Pipeline Partnerships: Two ongoing Phase 3 programs utilizing the 2+1 platform: ASP2138 with Astellas and Zaloridamide with Amgen.
• Platform Technology: XMAP 2+1 format (bivalent tumor targeting + single CD3) designed to enhance tumor selectivity and safety over 1+1 bispecifics; QSP models validate high tumor-to-normal killing ratios.
• Combination Strategies: Exploring rational combinations with PD-1 inhibitors (e.g., pembrolizumab) for earlier lines of treatment; avoiding VEGFR TKI combinations to minimize cumulative toxicity.

Market and Competitive Landscape:

• Target Market: Addressing the unmet need in post-immunotherapy and post-VEGFR TKI advanced clear cell RCC, representing ~9,000 eligible patients annually in the U.S. alone.
• Competitive Positioning: Claims 45% ORR in heavily pre-treated (triple-class exposed) patients exceeds current monotherapy standards (e.g., Tivozinib 10.5% ORR in similar settings).
• Differentiation: Unique "orthogonal" safety profile with non-cumulative toxicity post-priming, allowing sustained dosing compared to VEGFR TKIs and standard of care immunotherapies.
• Expansion Potential: High unmet need in MSS colorectal and lung cancers; potential to expand indications via ENPP3-positive patient selection.

Risks and Challenges:

• Clinical Development Risk: Dependency on successful initiation and positive data from the 2027 Phase 3 trial; regulatory acceptance of accelerated approval pathway remains unconfirmed.
• Safety Management: Initial dose-dependent toxicities (CRS, rash, transaminitis) during the priming phase require pre-medication; long-term durability of responses and potential for tumor progression in non-responders remain factors.
• Formulation Uncertainty: Final decision on IV vs. Sub-Q for commercial launch pending upcoming Sub-Q data in H1 2027.
• Competition: Rapidly evolving landscape in RCC with new approvals (Belzutafan/Levatmib) and existing standards of care (Cabozantinib, PD-1s).

Management Commentary and Tone:

• Tone: Highly confident and optimistic; management describes data as a "high watermark" for Phase 1 trials in RCC and emphasizes the platform's ability to solve selectivity issues in solid tumors.
• Strategic Focus: Emphasis on executing clinical trial excellence, advancing XMAP819 to pivotal studies, and establishing Zencore as a commercial-stage entity by 2030.
• Regulatory Strategy: Strong belief in the feasibility of accelerated approval for the triple-class exposed population, leveraging the robust lower bounds of ORR and durable response rates.

Analyst Questions and Answers:

• Accelerated Approval Requirements: Management estimates ~100 patients for the safety analysis pool and efficacy powering based on lower bound ORR and median duration of response (MDOR), rather than survival metrics.
• Combination Safety: Confidence in combining XMAP819 with PD-1 inhibitors due to lack of overlapping toxicity and favorable data from similar TCEs (e.g., Astellas' ASP2138, Tarlatamab).
• Sub-Q vs. IV: Sub-Q dosing historically reduces CRS and Cmax; data expected in H1 2027 will determine if Sub-Q becomes the primary presentation or a lifecycle optimization.
• Dose Selection: 400 µg/kg selected based on consistent safety profiles across 100/200/400 µg/kg cohorts, superior disease control rates, and QSP modeling indicating the top of the sigmoidal dose-response curve.
• Trial Design: Phase 3 aims to compare against Tivozinib (active control) for full approval; accelerated approval may utilize a single-arm cohort for the triple-class exposed subset.
• Scan Timing: Discussions on normalizing scan timing to 8–10 weeks to account for delayed responses and avoid misclassifying initial pseudo-progression as progression.
• Patient Demographics: Baseline IMDC risk scores reflect a genuine skew toward intermediate/poor risk (due to proper baseline calculation) rather than reclassification, underscoring the significance of the observed efficacy in high-need populations.

Other Key Points:

• Patient Case Study: Highlighted a 56-year-old patient with <25% ENPP3 expression who achieved a complete response lasting 16 months after prior failures with multiple VEGFR TKIs and HIF-2 inhibitors.
• Toxicity Management: Implementation of prophylactic tocilizumab on priming day 1 and pre-medication regimens (steroids, antihistamines) has significantly reduced CRS and rash incidence, enabling potential reduction in hospitalization monitoring.
• Durable Responses: Median time to response is 2.7 months, but ~25% of responses deepen over time, with some patients maintaining responses for nearly 2.5 years.
• Manufacturing: Drug substance and product stable for 60 months, facilitating long-term logistics and commercial readiness.
• Portfolio Breadth: XMAP819 serves as the anchor for expanding into other ENPP3-positive histologies, potentially creating a new standard of care in RCC and beyond.